文献速递传染病防控与疫情报告卫生政策与健康促进

印度医疗体系诊治的结核病患者耐药性出现的动态建模研究

Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study.
PubMed 文献 · Lancet Public Health · 2016-12-19

该研究构建动态马尔可夫模型模拟印度结核病流行,纳入复杂求医路径与耐药获得。若未来20年各机构结核病管理实践不变,预计异烟肼耐药发病率增加47%、耐多药结核病发病率增加152%、未治疗耐多药结核病患病率增加242%、耐多药结核感染风险增加275%。到2032年,约85%的耐多药结核病将为原发性耐多药结核病。

要点

  • 若管理实践不变,未来20年耐多药结核病发病率预计增加152%。
  • 到2032年,约85%的耐多药结核病将为原发性耐多药结核病。
  • 公立机构贡献87%的获得性耐多药结核病,与不规律服药相关。

核心结论

  • 研究预测印度结核病流行将从当前的药物敏感结核病逐渐转变为耐药结核病流行。
  • 亟需基于证据的策略改善各卫生部门的提供者实践和患者依从性以预防这一转变。

研究设计与样本

  • 研究构建动态马尔可夫模型代表印度结核病流行,包括反映复杂求医路径的概率框架。
  • 模型纳入潜在耐药和治疗过程中获得的耐药,并使用来自已发表文献的印度特异性流行病学数据。

主要发现

  • 若未来20年印度各机构结核病管理实践不变,预计异烟肼耐药发病率增加47%。
  • 预计耐多药结核病发病率增加152%,未治疗耐多药结核病患病率增加242%,耐多药结核感染风险增加275%。
  • 到2032年,估计85%的耐多药结核病为原发性耐多药结核病,而2012年仅为15%。
  • 公立机构贡献87%的获得性耐多药结核病,与不规律服药相关;其余来自私立机构,与治疗未完成相关。
  • 药师和非对抗疗法从业者不使用利福平治疗,但由于含异烟肼方案的不当使用率高和治疗不依从,会产生异烟肼耐药。

关键数值与推荐

  • 原文未报告关键数值与推荐的具体阈值或推荐条款。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: India has the highest number of patients with tuberculosis and multidrug-resistant tuberculosis in the world. We used a transmission model to project the emergence of drug resistance in India due to incorrect tuberculosis management practices in multiple sectors, including public and private providers, chemists, and non-allopathic practitioners. METHODS: We constructed a dynamic Markov model to represent India's tuberculosis epidemic, including a probabilistic framework reflecting complex treatment-seeking pathways. Underlying drug resistance and the acquisition of drug resistance during treatment were included. India-specific epidemiological data, including tuberculosis management practices, were obtained from published literature. Outcomes, which included annual risk of infection, incidence of new disease, prevalence of untreated tuberculosis, and tuberculosis-related mortality, were stratified by underlying drug resistance, as well as by health sector to understand how each sector contributes to the emergence of drug resistance. FINDINGS: If tuberculosis management practices across sectors in India remain unchanged over the next 20 years, we estimated a 47% increase in the incidence of isoniazid resistance, a 152% increase in multidrug-resistant tuberculosis incidence, a 242% increase in prevalent untreated multidrug-resistant tuberculosis, and a 275% increase in the risk of multidrug-resistant tuberculosis infection. By 2032, an estimated 85% of multidrug-resistant tuberculosis will be primary multidrug-resistant tuberculosis compared with only 15% in 2012. The public sector contributed 87% of acquired multidrug-resistant tuberculosis, related to irregular adherence; the remainder came from the private sector, related to treatment non-completion. Chemists and non-allopathic practitioners do not treat with rifampicin, but because of the high rates of inappropriate isoniazid-containing regimens, and treatment non-adherence, this would generate isoniazid resistance. INTERPRETATION: We predict a gradual transformation from the current epidemic of drug-susceptible tuberculosis to a drug-resistant epidemic. Evidence-based strategies to improve provider practices and patient adherence across health sectors are urgently needed to prevent this. FUNDING: United States Agency for International Development and the Canadian Institutes for Health Research.

来源:Lancet Public Health,查看原文。版权归原作者所有。

引用

  1. Law S, Piatek AS, Vincent C, et al. Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study. Lancet Public Health. 2016. PMID: 29249480. doi:10.1016/S2468-2667(16)30035-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。